The launch of donepezil (Aricept).

The launch of donepezil (Aricept), a specific treatment for patients with mild or moderate Alzheimer's disease, attracted intense interest. Clinicians and others were quot in the media as being optimistic about the drug's effectiveness, on the other hand concerned that NHS funding would be withheld or rough However, reaching consensus on the clinical rather than statistical importance of this unsalable article requires open debate, given the relatively small efficiency sizes and uncertainty over side weights in typical patients. Debate has been hampered because publication of the replete results of the main clinical trials has been delayed. This episode highlights several issues of general policy importance that must be resolv if access to the information requireed for clinical and other decision making is to be improved.

The launch of donepezil -- perceptions and reality

Alzheimer's disease is a for the use of all and devastating condition, and the launch of a specific treatment naturally attracted intense interest. The recently made known drug, donepezil (Aricept), an anticholinesterase agent was licensed in the United States in December 1996 with reports that it had produc "highly significant improvements in cognitive and clinical global assessments" in randomised trials lasting 30 weeks and had increased the proportion of "treatment successes" by means of 245%.[1]

The drug's launch three month later in the United Kingdom was welcomeed with optimism. The lay pres quot eminent clinicians as saying that donepezil "marks a sea change" in management of dementia,[2] that it should be seen as "a way to alleviate the carrying capacity of a terrible disease," and that it would "give expectancy to many people and their carers"[3] Several clinicians voiced fears about funding, including a illustration that "we must make permanent health authorities do not prove by experiment to hold back"[2] One refer toed journalist even suggested that inability to store treatments like donepezil could come in a mass move of all on the contrary the poor into private medical care, killing facing the NHS.[4]

Closer to the NH the Health Services Journal quot a professor as saving that using donepezil would bring to care costs, because it would halve the incidence of Alzheimer's disease.[5] The journal also reported that the NH Confederation (representing trusts and health authorities) welcomed the mix with drugs and called for government funding to pay for it. A spokesperson argued that as the physic would mainly bring savings in social care, the estimated annual richness of 200[pounds sterling] million could be switched from health to social services stocks It was largely left to the Alzheimer's Disease Society to introduce a note of caution into many of the reports on complaining of the unhelpful leaks about donepezil before its launch and suggesting that the medicine was likely to play a unostentatious role.[6]

The little information available from the clinical trials hints that the Alzheimer's Disease Society's caution may have been wise. According to the study's be in possession of clinicians, the additional treatment replications in the highly selected subject of attention group were predominantly of minimal clinical importance (see below). This mismatch between perceived benefits and the consideration data, together with the barriers to obtaining information, raises policy transactions of general importance in health care. These pertain tos fall into four main categories -- namely, the usefulness of the trials required for licensing, the publication of evidence, the communication of overall benefits to individuals, and the assessment of the impact forward the population.

Policy concerns

Trials and the evidence of drift size

Clinical trials for unsalable article licensing are designed to establish the efficacy and safety of fresh compounds. In the case of Alzheimer's disease, the United States aliment and Drug Administration set specific requirements for trials, including the ne for appropriate measures of outcome[7 8] The agency, recognising that changes in psychometric exhibition results alone might be trivial, propos that clinically useful general intents should also be determined by dint of clinical assessment.

Clinical assessment

For folks with Alzheimer's disease and their carers, benefits will hang on improvements in everyday functioning and quality of life." Changes in the capacity to perform activities of daily living were not considered crucial through American standards, although European draft criteria do include these. As still no claims have been made that donepezil changes the issue of any of these measures, although relevant data were mustered Therefore, the only available assessment of the drug's clinical benefits, other than the cognitive ordeal scores, is the clinician's ratings.

The scale used for clinical assessment was the clinicians' interview based impression of change ("plus" version; CIBIC-plus), "a semi-structured instrument, examining general, cognitive and behavioural functioning and activities of daily living, rated according to a study clinician based relating to his/her observations at an interview with the patient in combination with information supplied through a caregiver."[10] The seven point scale is ordinal, yet the ratings are: marked, moderate, minimal or no change for improvement or deterioration, and it would be absurd to refer to that the notional rating of 3 for marked improvement implies a proportionate change from the 2 for moderate improvement. Despite this, in such a manner called statistically significant mean changes in this score (of 035 for a 5 mg dose compared with placebo at 24 weeks) have been widely quot in promotional literature.